US69404D1081 - Common Stock
PACIFIC BIOSCIENCES OF CALIF
NASDAQ:PACB (11/22/2024, 8:00:02 PM)
After market: 1.84 +0.04 (+2.22%)1.8
+0.03 (+1.69%)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 796 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025
P: 16505218000
CEO: Christian O. Henry
Employees: 796
Website: https://www.pacb.com/
The rock star money manager is starting to roll with the rallying market.
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory...
/PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the...
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation...
Here you can normally see the latest stock twits on PACB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: